Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...